Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
Provides 10-year market exclusivity in EU upon regulatory approval DEVON, Pa., Feb. 28, 2022 (GLOBE…
Month: March 2022
Foghorn Therapeutics to Participate at the Cowen’s 42nd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) — Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a company…
Day One to Participate in the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN),…
Imago BioSciences to Participate in the Cowen 42nd Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Imago BioSciences, Inc. (“Imago”) (Nasdaq:…
Seer Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Outlook
Demonstrated tangible market progress and shipped 17 instruments through year end 2021 REDWOOD CITY, Calif.,…
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
Preliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4…
Berkeley Lights to Participate in Cowen 42nd Annual Health Care Conference
EMERYVILLE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader…
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing…
Angion Announces Participation in Upcoming Investment Conferences
UNIONDALE, N.Y., Feb. 28, 2022 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company…
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
Generated $15.1 million in full year 2021 EMPAVELI® (pegcetacoplan) net product revenues; demonstrated strong initial…
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
Phase 1 Trial of DT-216 in Patients with Friedreich Ataxia to Be Initiated Soon Topline…
Biomea Fusion Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
Phase I trial of BMF-219, an irreversible covalent menin inhibitor, is currently underway Plan to…
Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference
FOSTER CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the…
Kinnate Biopharma Inc. to Participate in the 42nd Annual Cowen Health Care Conference
SAN FRANCISCO and SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) — Kinnate Biopharma Inc. (Nasdaq:…
Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates
AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage…
BrainChip Appoints Antonio J. Viana as Chairman of the Board
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first…
Software AG Acquires StreamSets to Further Accelerate Rapid Growth in Hybrid Integration
StreamSets is a fast-growing, enterprise-grade provider of data integration for modern analytics with a four-year…